Katja Goričar1, Viljem Kovač, Vita Dolžan. 1. Pharmacogenetics Laboratory, Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Vrazov trg 2, 1000 Ljubljana, Slovenia.
Abstract
AIM: We evaluated the influence of genetic variability in translesion polymerases REV1 and REV3L on the outcome of cisplatin treatment in malignant mesothelioma patients. MATERIALS & METHODS: In total, 139 malignant mesothelioma patients were genotyped for seven tag SNPs in REV1 and REV3L. Logistic regression and Cox regression were used to assess the influence of SNPs on treatment outcome. RESULTS: Polymorphic REV1 rs3087403 allele and REV1 TGT haplotype were associated with increased risk for leukopenia (p = 0.013 and p = 0.047, respectively) and neutropenia (p = 0.048 and p = 0.024, respectively). REV3L rs465646, rs462779 and REV3L CCGG haplotype were significantly associated with longer overall survival (p = 0.007, p = 0.022 and p = 0.013, respectively). CONCLUSION: Our results suggest for the first time that REV1 and REV3L SNPs might serve as potential predictive markers of outcome of cisplatin-based chemotherapy. Original submitted 7 October 2013; Revision submitted 15 January 2014.
AIM: We evaluated the influence of genetic variability in translesion polymerases REV1 and REV3L on the outcome of cisplatin treatment in malignant mesotheliomapatients. MATERIALS & METHODS: In total, 139 malignant mesotheliomapatients were genotyped for seven tag SNPs in REV1 and REV3L. Logistic regression and Cox regression were used to assess the influence of SNPs on treatment outcome. RESULTS: Polymorphic REV1rs3087403 allele and REV1 TGT haplotype were associated with increased risk for leukopenia (p = 0.013 and p = 0.047, respectively) and neutropenia (p = 0.048 and p = 0.024, respectively). REV3Lrs465646, rs462779 and REV3L CCGG haplotype were significantly associated with longer overall survival (p = 0.007, p = 0.022 and p = 0.013, respectively). CONCLUSION: Our results suggest for the first time that REV1 and REV3L SNPs might serve as potential predictive markers of outcome of cisplatin-based chemotherapy. Original submitted 7 October 2013; Revision submitted 15 January 2014.
Authors: Mina Yeom; In-Hyeok Kim; Jae-Kwon Kim; KyeongJin Kang; Robert L Eoff; F Peter Guengerich; Jeong-Yun Choi Journal: Chem Res Toxicol Date: 2016-03-04 Impact factor: 3.739
Authors: Ning Zhu; Xuefeng Fang; Dan Li; Mengyuan Yang; Lizhen Zhu; Liping Zhong; Shanshan Weng; Juan Wang; Ying Yuan Journal: Am J Cancer Res Date: 2021-06-15 Impact factor: 6.166